Repros Therapeutics (RPRX)
Repros Therapeutics Debt to Equity Ratio: 0.00
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
RPRX Debt to Equity Ratio Rankings
| Overall | 99th percentile | 1 of 4262 |
| Sector | 99th percentile | 1 of 478 in Healthcare |
| Industry | 99th percentile | 1 of 146 in Biotechnology |
RPRX Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.00 | Jun 2007 |
| Maximum | 0.00 | Jun 2007 |
| Average | 0.00 |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these RPRX related companies
RPRX News
$RPRX will hold on just enough to convince u no sell off comin. when u least expect it, floor may become sinkhole.2 words: Liver Toxicity
about a day ago by ninanina65
about a day ago by ninanina65
FDA Says Repros Therapeutics (RPRX) Must Complete Integrated Safety Analysis of Oral Proellex
May 29, 4:03PM Street Insider
May 29, 4:03PM Street Insider
$RPRX - Trade Signal New - BTO @ 9.01-Limit w/6.55-Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/8ac9pbe
about 4 days ago by TraderFoxxx
about 4 days ago by TraderFoxxx
RT @TechEdgeTrades $RPRX keep it on ur radar.Could move quickly. Something behind all the insider buying http://stks.co/3zt9 all over itTNX
about 6 days ago by Tango13
about 6 days ago by Tango13
$RPRX keep it on ur radar.Play it smart.Could move quickly. Something behind all the insider buying http://chart.ly/6sqfmh3
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
$RPRX Lots of insider buying.Short term tgt 11.10 Break res at 10.11 could make a quick move to 24 http://chart.ly/llny4yy
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
@YngvaiMalmsteve I see a record of a reverse split on Oct15 2010 chart shows a high of 57 on 8/31/07 $RPRX http://chart.ly/iac2rul
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
$RPRX saw that coming, but now will wait for the swing short, too focused w/ KV.A up 58% intraday
about 6 days ago by HighGrowthFinancial
about 6 days ago by HighGrowthFinancial
@TechEdgeTrades $RPRX wasn't truly a $54 stock back in 2007...it was actually around $15...it's just done some reverse splits
about 6 days ago by YngvaiMalmsteve
about 6 days ago by YngvaiMalmsteve
$RPRX was on my radar but didn't pull the trigger,MACD still diverging.Was $54 stock back in 2007 http://chart.ly/qiddnhn
about 6 days ago by TechEdgeTrades
about 6 days ago by TechEdgeTrades
Notable 52-Week Highs and Lows of the Day 05/25: (LCC) (RPRX) High; (DCTH) (MXWL) (VIP) Low
May 25, 3:09PM Street Insider
May 25, 3:09PM Street Insider
Unusual 11 Mid-Day Movers 05/25: (GNOM) (UPI) (RPRX) Higher; (TLB) (DCTH) (PAY) Lower
May 25, 1:42PM Street Insider
May 25, 1:42PM Street Insider
RT @slimtrader $RPRX - Looks like $GNOM setting up for a run on 5min chart < Told ya
about 7 days ago by slimtrader
about 7 days ago by slimtrader
VeriFone Systems, Quest Software, Other Stocks Hit 52-Week Highs Friday
May 25, 12:32PM Fox Business
May 25, 12:32PM Fox Business
$RPRX man thought this would have came back already,it will to,when?lesson not to short stocks that trade thin,this could see $10 easy
about 7 days ago by HighGrowthFinancial
about 7 days ago by HighGrowthFinancial
$GENE http://stks.co/3yyR $ROSG $GENE $RPRX $GNOM $TELK Full blog post here http://stks.co/3yyS
about 7 days ago by LincolnList
about 7 days ago by LincolnList
Repros Updates Special Protocol Assessment Documentation for Pivotal Studies for Androxal
May 22, 4:05PM Benzinga
May 22, 4:05PM Benzinga
Repros Updates Special Protocol Assessment Documentation for Pivotal Studies for Androxal(R)
May 22, 4:01PM GlobeNewswire
May 22, 4:01PM GlobeNewswire
Repros (RPRX) Gets Confirmation that Required Androxal Phase 3 Documents Delivered
May 16, 4:03PM Street Insider
May 16, 4:03PM Street Insider
FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal(R)
May 16, 4:01PM GlobeNewswire
May 16, 4:01PM GlobeNewswire
Repros Therapeutics Inc.(R) Reports First Quarter 2012 Financial Results
May 15, 9:25AM GlobeNewswire
May 15, 9:25AM GlobeNewswire
Unusual 11 Mid-Day Movers 05/10: (ADY) (INSP) (RPRX) Higher; (SGI) (WFR) (ARX) Lower
May 10, 2:24PM Street Insider
May 10, 2:24PM Street Insider
Repros' Proellex(R)-V Clears Important Hurdle in Uterine Fibroid Program
Apr 30, 4:02PM GlobeNewswire
Apr 30, 4:02PM GlobeNewswire
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2011 Financial Results
Mar 27, 9:25AM GlobeNewswire
Mar 27, 9:25AM GlobeNewswire
Repros Therapeutics (RPRX) Announces FDA Meeting to Discuss Phase 3 Efficacy Studies of Androxal
Feb 27, 4:05PM Street Insider
Feb 27, 4:05PM Street Insider
FDA Grants Repros Meeting to Discuss Androxal(R) Phase 3 Study Design and Required Drug Dossier for NDA
Feb 27, 4:02PM GlobeNewswire
Feb 27, 4:02PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RPRX | 8.34 | +0.07 | +0.85% | 122.23M |
| RPM | 26.36 | -0.02 | -0.08% | 3.463B |
| REFR | 3.39 | +0.07 | +2.11% | 62.78M |
| REE | 4.07 | -0.20 | -4.68% | 188.86M |
| REDF | 4.21 | -0.38 | -8.28% | 134.17M |
| RE | 102.12 | +0.90 | +0.89% | 5.440B |
| QPSA | 2.93 | -0.06 | -2.01% | 108.24M |
| QMM | 0.44 | +0.01 | +1.15% | 66.26M |
| QLTY | 10.62 | +0.23 | +2.21% | 280.22M |
| QLTI | 7.61 | +0.03 | +0.40% | 371.12M |
